Department of Medicinal Chemistry and Molecular PharmacologyCollege of PharmacyPurdue UniversityWest LafayetteINUSA.
Program in Integrative Nutrition and Complex DiseasesTexas A&M UniversityCollege StationTXUSA.
Hepatol Commun. 2020 Dec 25;5(3):461-477. doi: 10.1002/hep4.1629. eCollection 2021 Mar.
The fatty acid desaturase 1 (FADS1), also known as delta-5 desaturase (D5D), is one of the rate-limiting enzymes involved in the desaturation and elongation cascade of polyunsaturated fatty acids (PUFAs) to generate long-chain PUFAs (LC-PUFAs). Reduced function of D5D and decreased hepatic expression, as well as low levels of LC-PUFAs, were associated with nonalcoholic fatty liver disease. However, the causal role of D5D in hepatic lipid homeostasis remains unclear. In this study, we hypothesized that down-regulation of FADS1 increases susceptibility to hepatic lipid accumulation. We used and models to test this hypothesis and to delineate the molecular mechanisms mediating the effect of reduced FADS1 function. Our study demonstrated that FADS1 knockdown significantly reduced cellular levels of LC-PUFAs and increased lipid accumulation and lipid droplet formation in HepG2 cells. The lipid accumulation was associated with significant alterations in multiple pathways involved in lipid homeostasis, especially fatty acid oxidation. These effects were demonstrated to be mediated by the reduced function of the peroxisome proliferator-activated receptor alpha (PPARα)-fibroblast growth factor 21 (FGF21) axis, which can be reversed by treatment with docosahexaenoic acid, PPARα agonist, or FGF21. , FADS1-knockout mice fed with high-fat diet developed increased hepatic steatosis as compared with their wild-type littermates. Molecular analyses of the mouse liver tissue largely corroborated the observations , especially along with reduced protein expression of PPARα and FGF21. Collectively, these results suggest that dysregulation in alters liver lipid homeostasis in the liver by down-regulating the PPARα-FGF21 signaling axis.
脂肪酸去饱和酶 1(FADS1),也称为 delta-5 去饱和酶(D5D),是参与多不饱和脂肪酸(PUFAs)去饱和和延伸级联反应生成长链多不饱和脂肪酸(LC-PUFAs)的限速酶之一。D5D 功能降低和肝表达减少,以及 LC-PUFAs 水平降低,与非酒精性脂肪性肝病有关。然而,D5D 在肝脂质稳态中的因果作用尚不清楚。在这项研究中,我们假设 FADS1 的下调会增加肝脂质积累的易感性。我们使用 和 模型来检验这一假设,并阐明介导 FADS1 功能降低效应的分子机制。我们的研究表明,FADS1 敲低显著降低了 HepG2 细胞中 LC-PUFAs 的细胞水平,并增加了脂质积累和脂滴形成。脂质积累与涉及脂质稳态的多个途径的显著改变有关,特别是脂肪酸氧化。这些影响被证明是通过过氧化物酶体增殖物激活受体α(PPARα)-成纤维细胞生长因子 21(FGF21)轴的功能降低介导的,用二十二碳六烯酸、PPARα 激动剂或 FGF21 处理可以逆转这些影响。, FADS1 敲除小鼠在高脂肪饮食喂养下比其野生型同窝仔鼠表现出明显的肝脂肪变性。对小鼠肝组织的分子分析在很大程度上证实了这些观察结果,尤其是 PPARα 和 FGF21 的蛋白表达降低。 总之,这些结果表明,FADS1 的失调通过下调 PPARα-FGF21 信号轴改变了肝脏的脂质稳态。